Direct thrombin inhibitors are superior to heparin in preventing death or myocardial infarction (MI) in patients with acute coronary syndromes (ACS), according to a meta-analysis of 11 randomized trials.
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.